Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Sep 20;8(1):11-21.
doi: 10.1038/nrendo.2011.151.

Management of the metabolic effects of HIV and HIV drugs

Todd T Brown  1 , Marshall J Glesby
Affiliations
Review

Management of the metabolic effects of HIV and HIV drugs

Todd T Brown et al. Nat Rev Endocrinol. .

Abstract

Morphologic and metabolic abnormalities, including subcutaneous adipose tissue wasting, central adipose tissue accumulation, dyslipidemia and disorders of glucose metabolism are common among HIV-infected patients receiving highly active antiretroviral therapy (HAART) and contribute to the risk of cardiovascular disease in this population. The pathogenesis of these disorders is due to complicated interactions between effects of chronic HIV infection, HAART medications and patient factors, including genetic susceptibility. HAART has transformed HIV into a chronic condition for many patients and as a result the majority of HIV-infected patients in many areas of the developed world will soon be aged ≥50 years. Given that metabolic and cardiovascular diseases increase with aging, knowledge of the optimal management of these conditions is essential for practitioners caring for HIV-infected patients, including endocrine subspecialists. This Review highlights the clinical management of these disorders, focusing on the latest evidence regarding the efficacy of treatment strategies, newly available medications and potential interactions between HAART medications and medications used to treat metabolic disorders.

PubMed Disclaimer

Conflict of interest statement

Competing interests

T. T. Brown declares associations with the following companies: Abbott, EMD Serono, Gilead, GlaxoSmithKline, Merck, Theratechnologies, Tibotec, ViiV Healthcare. M. J. Glesby declares associations with the following company: Pfizer. See the article online for full details of the relationships.

Figures

Figure 1
Figure 1
45-year-old HIV-infected woman with a) moderate to severe facial lipoatrophy with marked adipose tissue wasting in the malar areas with extension of adipose tissue wasting to buccal and temporal areas, and b) central lipohypertrophy with a large dorso-cervical fat pad. Permission obtained from the Endocrine Society © Brown, T. T. Approach to the human immunodeficiency virus-infected patient with lipodystrophy. J. Clin. Endocrinol. Metab. 93 (8), 2937–2945 (2008).
Figure 2
Figure 2
A 58-year-old HIV-infected man with severe visceral abdominal fat accumulation, umbilical hernia and diffuse subcutaneous lipoatrophy including loss of subcutaneous abdominal adipose tissue with resultant prominent appearance of veins.
See this image and copyright information in PMC

References

    1. Palella FJ, Jr, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860. - PubMed
    1. Detels R, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA. 1998;280:1497–1503. - PubMed
    1. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;352:1881–1883. - PubMed
    1. Lichtenstein KA, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr. 2003;32:48–56. - PubMed
    1. Jacobson DL, et al. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis. 2005;40:1837–1845. - PubMed

Publication types

MeSH terms

Substances